NexDx Changes Name to Ignyta to Reflect Burning Commitment to Catalyzing the Personalized Medicine Revolution
Published: Oct 09, 2012
Ignyta’s vision is to kindle the development and usage of the most accurate molecular diagnostic tests and precisely targeted therapeutics in autoimmune diseases (AID) and to extinguish AID through earlier, more enlightened diagnosis and treatment of patients worldwide.
“There is a dramatic revolution underway in personalized medicine, in which we are moving away from a one-size-fits-all approach to treating patients to a highly customized model of delivering the right drug to the right patient at the right time. The introduction of our new brand Ignyta reflects our broader participation across diagnostics and therapeutics, as well as our burning commitment to join this exciting movement and catalyze the personalized revolution,” said Jonathan Lim, M.D., CEO of Ignyta, Inc.
Dr. Lim added, “Ignyta symbolizes our aspiration of revolutionizing the quality of biomarkers and tests available to doctors and patients to help them make better informed, more individualized treatment decisions. We are ready and raring to translate the promise of ‘omics’ technologies into tangible patient benefit – the Ignyta brand captures our ambition of turning this promise into reality.”
About Ignyta, Inc.
Ignyta, Inc., located in San Diego, California, is a personalized medicine company developing revolutionary new products and services to customize diagnosis and treatment of patients with rheumatoid arthritis, lupus and other autoimmune diseases.
The company, launched in August 2011 by Jonathan E. Lim, M.D., former president, CEO and board director of Halozyme Therapeutics, Inc., and Gary S. Firestein, M.D., director of the Clinical and Translational Research Institute and Dean and Associate Vice Chancellor of Translational Medicine at UC San Diego, is a trailblazer in the application of “omics” technologies integrated with bioinformatics to the development and commercialization of novel biomarkers and tests for diagnostic and therapeutic applications in autoimmune diseases.
The scientific discoveries that fueled the founding of Ignyta were published in July 2012 in the Annals of the Rheumatic Diseases (http://bit.ly/QOZ8Zr). In June 2012, the company successfully closed a $2.1 million Series B financing led by City Hill Ventures, LLC (http://www.cityhillventures.com/) and a $500,000 capital term loan from Silicon Valley Bank (http://www.svb.com/). For more information, please visit: www.ignyta.com.
Media & investor contacts: